Read + Share

Amedeo Smart

Independent Medical Education


Read + Share

Saeed A, Mulukutla SR, Thoma F, Lemon L, et al. Comparison of Semaglutide or Dulaglutide Versus Empagliflozin for Risk for Death and Cardiovascular Outcomes Among Patients With Type 2 Diabetes : Two Target Trial Emulation Studies. Ann Intern Med 2025 Jun 17. doi: 10.7326/ANNALS-24-00775.
PMID: 40523289


Privacy Policy